SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
2020 · Nature · 1,618 citations
https://doi.org/10.1038/s41586-020-2622-0
S
Sunny Himansu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
6.5K
Citations
23
h-index
28
i10-index
Sunny Himansu is an academic researcher from Moderna Therapeutics (United States). The author has contributed to research in topics: HIV Research and Treatment & Mosquito-borne diseases and control & Immunotherapy and Immune Responses. The author has an h-index of 23, co-authored 41 publications.
ORCID: 0000-0002-7954-9674Papers by this author
worksOptimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
2019 · Molecular Therapy — Nucleic Acids · 841 citations
https://doi.org/10.1016/j.omtn.2019.01.013
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
2021 · Nature Medicine · 165 citations
https://doi.org/10.1038/s41591-021-01573-6
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections
2018 · Cell Reports · 124 citations
https://doi.org/10.1016/j.celrep.2018.11.082
Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice
2022 · Immunity · 57 citations
https://doi.org/10.1016/j.immuni.2022.09.003
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
2024 · Nature Immunology · 47 citations
https://doi.org/10.1038/s41590-024-01833-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat